Cell and Gene Therapy Web Page Announcement

Tokio Marine HCC – Stop Loss Group (TMHCC) is pleased to announce the launch of our new Cell & Gene Therapy website. TMHCC has partnered with Emerging Therapy Solutions® (ETS) for best in class service to positively impact the plan and patient.

ETS offers a wide variety of cell and gene therapy cost management opportunities. Our new Cell & Gene Therapy web page will be updated as new treatments are approved by the US Food and Drug Administration (FDA). We encourage you to use this page as a resource for ongoing developments and to learn more about how TMHCC in partnership with ETS can positively impact your clients’ healthcare plans.



What to Expect in The Future

In the near term pipeline, the FDA is expected to approve between 10 and 20 new cell and gene therapies per year between now and 2025. Nearer term, by the end of 2021, the FDA is expected to approve an additional investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy for multiple myeloma, ciltacabtagene autoleucel (cilta-cel), along with potential expanded indications for Tecartus™ (brexucabtagene autoleucel) to include adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) – with several more anticipated cell and gene therapy approvals on the early 2022 horizon. These two upcoming potential therapies are anticipated to be costly to cover – in the hundreds of thousands of dollars – and would result in new treatment options for very prevalent conditions. To learn more and stay current on what’s coming, follow emergingtherapies.com.

About Emerging Therapy Solutions

Emerging Therapy Solutions® (ETS) helps reinsurance and stop-loss payers, health plans and self-funded employers manage the risks associated with high-cost therapies for rare and complex conditions. We offer a comprehensive suite of services for solid organ and bone marrow transplants, cell and gene therapies, and other highly specialized therapies.







For producer use only. Not for public distribution.
Copyright 2021, Tokio Marine HCC. Tokio Marine HCC is a member of the Tokio Marine Group of Companies.

Tokio Marine HCC - Stop Loss Group | Corporate Headquarters | 225 TownPark Drive NW, Suite 350 | Kennesaw, GA 30144

Tokio Marine HCC - Stop Loss Group respects your privacy. We do not rent, sell or exchange email addresses. Please see our Privacy Policy for more information. If you do not wish to receive any emails concerning Tokio Marine HCC - Stop Loss Group's policies, changes and events, please click below to unsubscribe.

Click here to unsubscribe to all emails from TMHCC.


TMHCC-E2096 092321